Despite recent progress, significant barriers remain to making psychedelic-assisted therapies widely accessible. For-profit companies often lack the motivation to expand access to underserved communities, as capital incentives are limited. Governments are also hesitant to fund treatments involving historically stigmatized substances. Learn about the efforts that are underway to prioritize MDMA-assisted therapy for communities facing high levels of trauma and limited access to care, focusing on expanding availability where it is most needed, both domestically and globally.